Lamoga-25/Lamoga-50/Lamoga-100

Lamoga-25/Lamoga-50/Lamoga-100

lamotrigine

Manufacturer:

Unison

Distributor:

F.C.P.
Concise Prescribing Info
Contents
Lamotrigine
Indications/Uses
Adjunctive or monotherapy in the treatment of epilepsy, partial & generalised seizures, including tonic-clonic seizures & seizures associated w/ Lennox-Gastaut syndrome in adults >18 yr & adolescent 12-18 yr, & childn ≥2 yr (adjunct treatment only). Prevention of mood episodes in bipolar disorder, predominantly by preventing depressive episodes in adult ≥18 yr.
Dosage/Direction for Use
Adjunctive or monotherapy in the treatment of epilepsy, for partial & generalised seizures, including tonic-clonic seizures & seizures associated w/ Lennox-Gastaut syndrome Adult >18 yr & adolescent 12-18 yr Monotherapy 25 mg once daily for 2 wk, then 50 mg once daily for 2 wk. May be increased by max 50-100 mg every 1-2 wk. Maintenance: 100-200 mg (once daily or as 2 divided doses). Add-on therapy w/ valproate 25 mg every alternate day for 2 wk. May be increased by max 25-50 mg every 1-2 wk. Maintenance: 100-200 mg/day given once daily or in 2 divided doses. Add-on therapy w/ phenytoin, carbamazepine, phenobarb, primidone or other lamotrigine glucuronidation inducer 50 mg once daily for 2 wk, then 100 mg/day in 2 divided doses for 2 wk. May be increased by 100 mg every 1-2 wk. Maintenance: 200-400 mg/day in 2 divided doses. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 25 mg once daily for 2 wk then 50 mg daily for 2 wk. May be increased by 50-100 mg every 1-2 wk. Maintenance: 100-200 mg once daily or in 2 divided doses. Childn 2-12 yr Add-on therapy w/ valproate 0.15 mg/kg body wt given once daily for 2 wk, then 0.3 mg/kg/day once daily for 2 wk. May be increased by 0.3 mg/kg every 1-2 wk. Maintenance: 1-5 mg/kg body wt/day given once daily or in 2 divided doses to max 200 mg/day. Add-on therapy w/ phenytoin, carbamazepine, phenobarb, primidone or other lamotrigine glucuronidation inducer 0.6 mg/kg/day, then 1.2 mg/kg/day. Administer in 2 divided doses for 2 wk. May be increased by max 1.2 mg/kg every 1-2 wk. Maintenance: 5-15 mg/kg/day given in 2 divided doses. Max: 400 mg/day. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 0.3 mg/kg body wt/day, then 0.6 mg/kg body wt/day. To be given once daily or 2 divided doses for 2 wk. May be increased by 0.6 mg/kg every 1-2 wk. Maintenance: 1-10 mg/kg/day given once daily or in 2 divided doses to max 200 mg/day. Prevention of mood episodes in bipolar disorder, predominantly by preventing depressive episodes Adult ≥18 yr Adjunct therapy w/ valproate 25 mg every alternate day for 2 wk, then 25 mg once daily for 2 wk. May be increased to 50 mg once daily (or 2 divided doses) in wk 5. Target stabilization: 100 mg once daily or in 2 divided doses, may be increased to 200 mg/day. Adjunct therapy w/ phenytoin, carbamazepine, phenobarb, primidone or other lamotrigine glucuronidation inducer 50 mg once daily for 2 wk, then 100 mg in 2 divided doses for 2 wk, increased to 200 mg/day in 2 divided doses in wk 5, may be increased in wk 6 to 300 mg/day. Target stabilization: 400 mg/day in 2 divided doses which may be given from wk 7. Monotherapy or adjunct therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 25 mg once daily for 2 wk, then 50 mg once daily or 2 divided doses for 2 wk. Increase to 100 mg/day on wk 5. Target stabilization: 200 mg once daily or 2 divided doses.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Skin rash & fever during first 8 wk of therapy. History of allergy/rash to other antiepileptic drugs. Do not restart in patients who have discontinued due to rash asceptic meningitis. Liver & renal disease. Monitor for clinical worsening & suicidality. Concomitant use w/ other lamotrigine-containing prep. Avoid abrupt w/drawal (reduce dosage over a period of 2 wk). Childn <18 yr w/ major depressive disorder & other psychiatric disorders. May impair ability to drive or operate machinery. Women on hormonal therapy. Pregnancy & lactation. Childn <2 yr.
Adverse Reactions
Skin rash, aggression, irritability, headache, somnolence, insomnia, dizziness, tremor, ataxia, nystagmus, diplopia, blurred vision, nausea, vomiting, diarrhea, tiredness, agitation, arthralgia, pain, back pain.
Drug Interactions
Enhanced metabolism w/ phenytoin, carbamazepine, phenobarb, primidone, rifampicin, lopinavir/ritonavir, atazanavir/ritonavir. Reduced metabolism w/ valproate. Reduced conc w/ hormonal contraceptive. Increased topiramate conc.
ATC Classification
N03AX09 - lamotrigine ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Lamoga-100 tab 100 mg
Packing/Price
3 × 10's
Form
Lamoga-50 tab 50 mg
Packing/Price
3 × 10's
Form
Lamoga-25 tab 25 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in